Reimbursed Care Access in Czechia

From 1 January 2026 Czech law and accompanying government regulations explicitly permit the prescription and supervised administration of individually‑prepared medicinal products containing psilocybin for narrowly defined clinical indications (e.g., severe treatment‑resistant depression, cancer‑related depression and rapidly deteriorating neuropsychiatric states) under strict protocols and licensed facilities. The government regulation implementing these changes (government regulation no. 552/2025 Sb. and related amendments to the lists of substances usable for medicinal preparations) sets precise limits on who may prescribe and administer psilocybin (psychiatrists or psychiatrists with defined psychotherapy qualifications), maximum per‑month dosing and procedural safeguards; the regulation was published with effect from 1 January 2026. # #

Operationally, the Ministry of Health and specialist bodies (the Psychiatric Society / guidelines being developed by the National Institute of Mental Health and professional societies) have responsibility for training, procedural standards and facility accreditation; those implementing rules emphasize multi‑hour supervised dosing sessions, two qualified therapists present, integration psychotherapy and defined maximum dose and dose‑frequency (e.g., caps described in draft/press materials such as three doses/month up to a specified total). Implementation guidance and pharmacy/institutional ordering rely on amendments that add psilocybin to the statutory list of substances that may be used to prepare individually compounded medicinal products, thereby enabling hospital pharmacies and special authorised facilities to prepare the medicinal product legally. # #

Reimbursement: the legal change does not automatically equate to universal public reimbursement. Government and professional sources note that negotiations with insurers and placement on reimbursement lists (or creation of a specific funded programme) remain outstanding; as a result, initial access will be limited and likely private/self‑pay or via pilot programmes until Czech public payers (Všeobecná zdravotní pojišťovna and other health insurers) define coverage criteria and coding. Multiple ministry and press communications state that cost/coverage discussions with insurers will determine the breadth of access beyond pilot/clinical settings. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine nasal spray (Spravato) is a registered medicinal product in the Czech Republic (marketing‑authorisation holder: Janssen‑Cilag s.r.o.; SÚKL product record published) and is administered under certified supervised conditions. The SÚKL registry shows an active registration entry for esketamine (Spravato). #

Reimbursement and practical access: registration confirms an approved medicinal product and a formal regulatory framework for in‑clinic administration, but registration alone does not guarantee full public reimbursement. National SÚKL listings (including the Czech list of medicines not reimbursed by public health insurance) and payer practice indicate that some novel psychiatric medications may not be automatically or fully covered by all public insurers; reimbursement decisions typically require placement on the public reimbursement list or specific programme agreements. In practice in Czechia, Spravato is available in specialised centres but patients/institutions must confirm whether the specific treatment episodes and observation services are reimbursed by the relevant health insurer or remain out‑of‑pocket or subject to restricted funding. #

Ketamine (the racemate, injectable formulations and approved anaesthetic products) is an authorised medicinal substance in Czechia for anaesthesia/analgesia and is commonly used off‑label in psychiatry (ketamine‑assisted therapy, IV/IM/subcutaneous or oral formulations) for treatment‑resistant depression and other psychiatric indications. Clinical services and specialist outpatient clinics in Prague and other cities offer ketamine‑assisted psychotherapy and infusion protocols; such use is legally permitted as off‑label prescribing by qualified physicians under Czech practice rules. # #

Reimbursement: because psychiatric uses of ketamine are off‑label, routine full reimbursement by public health insurers is inconsistent. Some providers report contracts with several Czech insurers that cover parts of the clinical pathway (psychiatric outpatient services, consultations and selected procedures), and in practice clinics negotiate coverage on a case‑by‑case basis; however, many ketamine psychiatric services remain partially self‑pay or rely on mixed payer arrangements. Clinicians and clinics typically document medical necessity and may seek prior authorisation, but broad national reimbursement policies for ketamine‑for‑depression are not standardised as of early 2026. #

Currently classified as a strictly controlled substance under Czech narcotics scheduling (production, possession and distribution of DMT are restricted); there are narrow exceptions for authorised research and complex legal nuances around plant preparations (e.g., ayahuasca) tied to DMT content and judicial interpretation of quantity thresholds. A Czech Supreme Court opinion and government regulation identify quantity thresholds with legal consequences (e.g., certain small‑amount thresholds and limits for ayahuasca preparations referenced in court guidance). # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (There is no national authorised therapeutic ibogaine programme; access is therefore limited to research contexts if authorised.) #

Possession or distribution of ayahuasca that contains controlled DMT is illegal except in narrowly authorised research; Czech jurisprudence and government regulation treat DMT‑containing brews as subject to narcotics law with quantity thresholds used in judicial practice to distinguish ‘small’ from ‘larger’ amounts. Possession/distribution of ayahuasca containing DMT above established small‑amount thresholds has led to prosecution in past cases. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. (Mescaline and mescaline‑containing cacti are controlled under Czech narcotics legislation except where specific plant possession rules or small‑quantity administrative rules may apply.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Designer phenethylamines in the 2C family are controlled and enforcement treats distribution and possession as criminal offences beyond de minimis personal quantities. #